Evidence map›Paper›PMID 38557112›Full record

ArticleAntimicrobial agents and chemotherapy2024

Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.

Teclegiorgis Gebremariam, Sondus Alkhazraji, Yiyou Gu, Laura K Najvar, Katyna Borroto-Esoda, Thomas F Patterson, Scott G Filler, Nathan P Wiederhold, Ashraf S Ibrahim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Microbiology and molecular biology reviews : MMBR · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Teclegiorgis GebremariamThe Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Sondus AlkhazrajiThe Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Yiyou GuThe Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Laura K NajvarUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Katyna Borroto-EsodaScynexis Inc., Jersey City, New Jersey, USA.
Thomas F PattersonUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Scott G FillerThe Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA.
Nathan P WiederholdUniversity of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Ashraf S IbrahimThe Lundquist Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA.ORCID 0000-0003-3787-8530
University of California, Los Angeles · USThe University of Texas Health Science Center at San Antonio · USScynexis (United States) · US

Funding

Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
Iron Uptake and Mucormycosis PathogenesisR56AI063503 · NIAID · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI IBRAHIM, ASHRAF S. · 2005 to 2005
$281k
NIAID NIH HHS R01 AI063503NIAID NIH HHS R56 AI063503
6 · The paper itself

Abstract

Ibrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer β-(1,3)-D-glucan by inhibiting the enzyme glucan synthase. We evaluated the

Indexed as

Amphotericin BAntifungal AgentsGlycosidesMucormycosisNeutropeniaTriterpenesAnimalsDisease Models, AnimalDrug Therapy, CombinationFemaleLung Diseases, FungalMiceMucorRhizopusTriazolesAmphotericin BAntifungal AgentsGlycosidesibrexafungerpliposomal amphotericin BposaconazoleTriazolesTriterpenescombination therapyIbrexafungerpinfection modelliposomal amphotericin BmousemucormucormycosisposaconazoleRhizopus

Identifiers

PMID38557112
PMCPMC11064560
OpenAlexW4393387292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.